Contribution of brain inflammation to neuronal cell death in neuronopathic forms of Gaucher's disease

Brain

Volumn 135, Issue 6, 2012, Pages 1724-1735

  Vitner, Einat B ^a   Farfel Becker, Tamar ^a   Eilam, Raya ^a   Biton, Inbal ^a   Futerman, Anthony H ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Gaucher's disease; lysosomal storage disorders; neuroinflammation

Indexed keywords

3 NITROTYROSINE; COLONY STIMULATING FACTOR 1; IBUPROFEN; INTERLEUKIN 1BETA; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MESSENGER RNA; MINOCYCLINE; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CELL ACTIVATION; CELL DEATH; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; ENCEPHALITIS; FEMALE; GAUCHER DISEASE; GENE EXPRESSION; MALE; MICROGLIA; MOUSE; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

EID: 84861552789     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/aws095     Document Type: Article

References (45)

1. Ahmad R, Rasheed Z, Ahsan H. Biochemical and cellular toxicology of peroxynitrite: implications in cell death and autoimmune phenomenon. Immunopharmacol Immunotoxicol 2009; 31: 388-96.
2. Andjelkovic AV, Pachter JS. Characterization of binding sites for chemo-kines MCP-1 and MIP-1alpha on human brain microvessels. J Neurochem 2000; 75: 1898-906.
3. Ausseil J, Desmaris N, Bigou S, Attali R, Corbineau S, Vitry S, et al. Early neurodegeneration progresses independently of microglial activation by heparan sulfate in the brain of mucopolysaccharidosis IIIB mice. PLoS One 2008; 3: e2296.
4. Barak V, Acker M, Nisman B, Kalickman I, Abrahamov A, Zimran A, et al. Cytokines in Gaucher's disease. Eur Cytokine Netw 1999; 10: 205-10.
5. Barnum CJ, Tansey MG. Modeling neuroinflammatory pathogenesis of Parkinson's disease. Prog Brain Res 2010; 184: 113-32.
6. Block ML, Hong JS. Microglia and inflammation-mediated neurodegen-eration: multiple triggers with a common mechanism. Prog Neurobiol 2005; 76: 77-98.
7. Block ML, Zecca L, Hong JS. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci 2007; 8: 57-69.
8. Brabers NA, Nottet HS. Role of the pro-inflammatory cytokines TNF-alpha and IL-1beta in HIV-associated dementia. Eur J Clin Invest 2006; 36: 447-58.
9. Enquist IB, Lo Bianco C, Ooka A, Nilsson E, Mansson JE, Ehinger M, et al. Murine models of acute neuronopathic Gaucher disease. Proc Natl Acad Sci USA 2007; 104: 17483-8.
10. Farfel-Becker T, Vitner E, Dekel H, Leshem N, Enquist IB, Karlsson S, et al. No evidence for activation of the unfolded protein response in neuronopathic models of Gaucher disease. Hum Mol Genet 2009; 18: 1482-8.
11. Farfel-Becker T, Vitner EB, Futerman AH. Animal models for Gaucher disease research. Dis Model Mech 2011a; 4: 746-52.
12. Farfel-Becker T, Vitner EB, Pressey SN, Eilam R, Cooper JD, Futerman AH. Spatial and temporal correlation between neuron loss and neuroinflammation in a mouse model of neuronopathic Gaucher disease. Hum Mol Genet 2011b; 20: 1375-86.
13. German DC, Liang CL, Song T, Yazdani U, Xie C, Dietschy JM. Neurodegeneration in the Niemann-Pick C mouse: glial involvement. Neuroscience 2002; 109: 437-50.
14. Graus-Porta D, Blaess S, Senften M, Littlewood-Evans A, Damsky C, Huang Z, et al. Beta1-class integrins regulate the development of laminae and folia in the cerebral and cerebellar cortex. Neuron 2001; 31: 367-79.
15. Gupta N, Oppenheim IM, Kauvar EF, Tayebi N, Sidransky E. Type 2 Gaucher disease: phenotypic variation and genotypic heterogeneity. Blood Cells Mol Dis 2011; 46: 75-84.
16. Henry CJ, Huang Y, Wynne A, Hanke M, Himler J, Bailey MT, et al. Minocycline attenuates lipopolysaccharide (LPS)-induced neuroinflammation, sickness behavior, and anhedonia. J Neuroinflammation 2008; 5: 15.
17. Hollak CE, Evers L, Aerts JM, van Oers MH. Elevated levels of M-CSF, sCD14 and IL8 in type 1 Gaucher disease. Blood Cells Mol Dis 1997; 23: 201-12.
18. Hong YB, Kim EY, Jung SC. Upregulation of proinflammatory cytokines in the fetal brain of the Gaucher mouse. J Korean Med Sci 2006; 21: 733-8.
19. Jeyakumar M, Smith DA, Williams IM, Borja MC, Neville DC, Butters TD, et al. NSAIDs increase survival in the Sandhoff disease mouse: synergy with N-butyldeoxynojirimycin. Ann Neurol 2004; 56: 642-9.
20. Jeyakumar M, Thomas R, Elliot-Smith E, Smith DA, van der Spoel AC, d'Azzo A, et al. Central nervous system inflammation is a hallmark of pathogenesis in mouse models of GM1 and GM2 gangliosidosis. Brain 2003; 126: 974-87.
21. Jmoudiak M, Futerman AH. Gaucher disease: pathological mechanisms and modern management. Br J Haematol 2005; 129: 178-88.
22. Lee YJ, Han SB, Nam SY, Oh KW, Hong JT. Inflammation and Alzheimer's disease. Arch Pharm Res 2010; 33: 1539-56.
23. Min JK, Kim YM, Kim SW, Kwon MC, Kong YY, Hwang IK, et al. TNF-related activation-induced cytokine enhances leukocyte adhesiveness: induction of ICAM-1 and VCAM-1 via TNF receptor-associated factor and protein kinase C-dependent NF-kappaB activation in endo-thelial cells. J Immunol 2005; 175: 531-40.
24. Ohmi K, Greenberg DS, Rajavel KS, Ryazantsev S, Li HH, Neufeld EF. Activated microglia in cortex of mouse models of mucopolysacchari-doses I and IIIB. Proc Natl Acad Sci USA 2003; 100: 1902-07.
25. Pelled D, Shogomori H, Futerman AH. The increased sensitivity of neurons with elevated glucocerebroside to neurotoxic agents can be reversed by imiglucerase. J Inherit Metab Dis 2000; 23: 175-84.
26. Ransohoff RM. Chemokines and chemokine receptors: standing at the crossroads of immunobiology and neurobiology. Immunity 2009; 31: 711-21.
27. Shachar T, Bianco CL, Recchia A, Wiessner C, Raas-Rothschild A, Futerman AH. Lysosomal storage disorders and Parkinson's disease: Gaucher disease and beyond. Mov Disord 2011; 26: 1593-604.
28. Sidransky E. Gaucher disease: complexity in a "simple" disorder. Mol Genet Metab 2004; 83: 6-15.
29. Smith D, Wallom KL, Williams IM, Jeyakumar M, Platt FM. Beneficial effects of anti-inflammatory therapy in a mouse model of Niemann-Pick disease type C1. Neurobiol Dis 2009; 36: 242-51.
30. Stamatovic SM, Shakui P, Keep RF, Moore BB, Kunkel SL, Van Rooijen N, et al. Monocyte chemoattractant protein-1 regulation of blood-brain barrier permeability. J Cereb Blood Flow Metab 2005; 25: 593-606.
31. Streit WJ, Walter SA, Pennell NA. Reactive microgliosis. Prog Neurobiol 1999; 57: 563-81.
32. Sun Y, Liou B, Ran H, Skelton MR, Williams MT, Vorhees CV, et al. Neuronopathic Gaucher disease in the mouse: viable combined selective saposin C deficiency and mutant glucocerebrosidase (V394L) mice with glucosylsphingosine and glucosylceramide accumulation and progressive neurological deficits. Hum Mol Genet 2010; 19: 1088-97.
33. Sun Y, Ran H, Liou B, Quinn B, Zamzow M, Zhang W, et al. Isofagomine in vivo effects in a neuronopathic Gaucher disease mouse. PLoS One 2011; 6: e19037.
34. Szabo C, Ischiropoulos H, Radi R. Peroxynitrite: biochemistry, patho-physiology and development of therapeutics. Nat Rev Drug Discov 2007; 6: 662-80.
35. Tezel G. TNF-alpha signaling in glaucomatous neurodegeneration. Prog Brain Res 2008; 173: 409-21.
36. Tybulewicz VL, Tremblay ML, LaMarca ME, Willemsen R, Stubblefield BK, Winfield S, et al. Animal model of Gaucher's disease from targeted disruption of the mouse glucocerebrosidase gene. Nature 1992; 357: 407-10.
37. Vitkovic L, Maeda S, Sternberg E. Anti-inflammatory cytokines: expression and action in the brain. Neuroimmunomodulation 2001; 9: 295-312.
38. Vitner EB, Dekel H, Zigdon H, Shachar T, Farfel-Becker T, Eilam R, et al. Altered expression and distribution of cathepsins in neuronopathic forms of Gaucher disease and in other sphingolipidoses. Hum Mol Genet 2010a; 19: 3583-90.
39. Vitner EB, Platt FM, Futerman AH. Common and uncommon pathogenic cascades in lysosomal storage diseases. J Biol Chem 2010b; 285: 20423-7.
40. Wada R, Tifft CJ, Proia RL. Microglial activation precedes acute neurodegeneration in Sandhoff disease and is suppressed by bone marrow transplantation. Proc Natl Acad Sci USA 2000; 97: 10954-9.
41. Willemsen R, Tybulewicz V, Sidransky E, Eliason WK, Martin BM, LaMarca ME, et al. A biochemical and ultrastructural evaluation of the type 2 Gaucher mouse. Mol Chem Neuropathol 1995; 24: 179-92.
42. Wong K, Sidransky E, Verma A, Mixon T, Sandberg GD, Wakefield LK, et al. Neuropathology provides clues to the pathophysiology of Gaucher disease. Mol Genet Metab 2004; 82: 192-207.
43. Wu YP, Proia RL. Deletion of macrophage-inflammatory protein 1 alpha retards neurodegeneration in Sandhoff disease mice. Proc Natl Acad Sci USA 2004; 101: 8425-30.
44. Yamaguchi Y, Inatani M, Matsumoto Y, Ogawa J, Irie F. Roles of heparan sulfate in mammalian brain development current views based on the findings from Ext1 conditional knockout studies. Prog Mol Biol Transl Sci 2010; 93: 133-52.
45. Yap TL, Gruschus JM, Velayati A, Westbroek W, Goldin E, Moaven N, et al. Alpha-synuclein interacts with glucocerebrosidase providing a molecular link between Parkinson and Gaucher diseases. J Biol Chem 2011; 286: 28080-8.